m+Medelevator.RU
← Поиск публикаций
Journal of the American College of Cardiology · 2023

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review.

СтатьяОбзорПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Figtree Gemma A, Vernon Stephen T, Harmer Jason A, Gray Michael P, Arnott Clare, Bachour Eric, Barsha Giannie, Brieger David, Brown Alex, Celermajer David S, Channon Keith M, Chew Nicholas W S, Chong James J H, Chow Clara K, Cistulli Peter A, Ellinor Patrick T, Grieve Stuart M, Guzik Tomasz J, Hagström Emil, Jenkins Alicia, Jennings Garry, Keech Anthony C, Kott Katharine A, Kritharides Leonard, Mamas Mamas A, Mehran Roxana, Meikle Peter J, Natarajan Pradeep, Negishi Kazuaki, O'Sullivan John, Patel Sanjay, Psaltis Peter J, Redfern Julie, Steg Philippe G, Sullivan David R, Sundström Johan, Vogel Birgit, Wilson Andrew, Wong Dennis, Bhatt Deepak L, Kovacic Jason C, Nicholls Stephen J, CRE for CAD Collaborators

Аннотация

Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты